Concepts (189)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Atrial Function, Left | 5 | 2018 | 82 | 2.31 | Why? |
| Echocardiography | 15 | 2020 | 3661 | 1.66 | Why? |
| Myocardial Contraction | 2 | 2018 | 123 | 1.34 | Why? |
| Ventricular Function, Left | 5 | 2018 | 1555 | 1.04 | Why? |
| Hypertrophy, Left Ventricular | 3 | 2018 | 219 | 0.86 | Why? |
| Diabetic Cardiomyopathies | 1 | 2018 | 79 | 0.69 | Why? |
| Mitral Valve Insufficiency | 2 | 2018 | 302 | 0.66 | Why? |
| Aminobutyrates | 1 | 2017 | 142 | 0.63 | Why? |
| Ventricular Dysfunction, Left | 2 | 2018 | 993 | 0.63 | Why? |
| Heart Ventricles | 4 | 2018 | 1139 | 0.59 | Why? |
| Tetrazoles | 1 | 2017 | 262 | 0.57 | Why? |
| Heart Failure | 7 | 2020 | 6638 | 0.56 | Why? |
| Atrial Fibrillation | 5 | 2018 | 2320 | 0.54 | Why? |
| Heart | 3 | 2018 | 1791 | 0.52 | Why? |
| Heart Diseases | 3 | 2020 | 3503 | 0.51 | Why? |
| Biomechanical Phenomena | 3 | 2018 | 291 | 0.46 | Why? |
| Stroke Volume | 7 | 2018 | 2153 | 0.43 | Why? |
| Hypertension | 5 | 2018 | 8895 | 0.40 | Why? |
| Ventricular Remodeling | 3 | 2018 | 349 | 0.40 | Why? |
| Acute Coronary Syndrome | 2 | 2020 | 2107 | 0.38 | Why? |
| Echocardiography, Doppler | 1 | 2010 | 269 | 0.36 | Why? |
| Echocardiography, Doppler, Pulsed | 2 | 2018 | 40 | 0.35 | Why? |
| Cardiomegaly, Exercise-Induced | 2 | 2017 | 10 | 0.34 | Why? |
| Heart Valve Prosthesis Implantation | 1 | 2013 | 552 | 0.33 | Why? |
| Aortic Valve Stenosis | 1 | 2013 | 741 | 0.29 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2017 | 3892 | 0.22 | Why? |
| Infection Control | 2 | 2020 | 23131 | 0.22 | Why? |
| Edema, Cardiac | 1 | 2020 | 33 | 0.22 | Why? |
| Cardiology | 4 | 2019 | 2873 | 0.20 | Why? |
| Water-Electrolyte Balance | 1 | 2020 | 136 | 0.20 | Why? |
| Microvascular Angina | 1 | 2018 | 19 | 0.19 | Why? |
| Dipyridamole | 1 | 2018 | 52 | 0.19 | Why? |
| Myocardium | 3 | 2020 | 2323 | 0.18 | Why? |
| Atrial Remodeling | 1 | 2018 | 31 | 0.18 | Why? |
| Diuretics | 1 | 2020 | 326 | 0.18 | Why? |
| Echocardiography, Stress | 1 | 2018 | 65 | 0.18 | Why? |
| Reflex | 1 | 2017 | 22 | 0.17 | Why? |
| Cardiomyopathies | 2 | 2017 | 997 | 0.17 | Why? |
| Practice Guidelines as Topic | 3 | 2018 | 15421 | 0.17 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.17 | Why? |
| Brachial Artery | 1 | 2017 | 107 | 0.17 | Why? |
| Metabolism, Inborn Errors | 1 | 2017 | 51 | 0.16 | Why? |
| Arterial Pressure | 1 | 2018 | 208 | 0.16 | Why? |
| Carotid Intima-Media Thickness | 1 | 2017 | 179 | 0.16 | Why? |
| Mitochondrial Diseases | 1 | 2017 | 62 | 0.16 | Why? |
| Valsartan | 1 | 2017 | 206 | 0.16 | Why? |
| Biphenyl Compounds | 1 | 2017 | 249 | 0.16 | Why? |
| Sympathetic Nervous System | 1 | 2017 | 111 | 0.16 | Why? |
| Pulmonary Edema | 1 | 2020 | 430 | 0.15 | Why? |
| Asymptomatic Diseases | 2 | 2018 | 3444 | 0.15 | Why? |
| Competitive Behavior | 1 | 2016 | 111 | 0.15 | Why? |
| Fluid Therapy | 1 | 2020 | 628 | 0.15 | Why? |
| Personal Protective Equipment | 1 | 2020 | 15978 | 0.15 | Why? |
| Autonomic Nervous System | 1 | 2017 | 148 | 0.15 | Why? |
| Echocardiography, Three-Dimensional | 1 | 2016 | 135 | 0.15 | Why? |
| Antirheumatic Agents | 2 | 2020 | 3023 | 0.14 | Why? |
| Research Support as Topic | 1 | 2019 | 327 | 0.14 | Why? |
| Heart Atria | 1 | 2017 | 267 | 0.14 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 1 | 2020 | 520 | 0.14 | Why? |
| Elasticity Imaging Techniques | 1 | 2017 | 194 | 0.14 | Why? |
| Fractional Flow Reserve, Myocardial | 1 | 2016 | 173 | 0.14 | Why? |
| Myocardial Revascularization | 1 | 2016 | 267 | 0.14 | Why? |
| Predictive Value of Tests | 4 | 2018 | 9537 | 0.14 | Why? |
| Reproducibility of Results | 5 | 2020 | 11304 | 0.13 | Why? |
| Troponin | 1 | 2020 | 1058 | 0.13 | Why? |
| Mitral Valve | 1 | 2017 | 342 | 0.13 | Why? |
| Stress, Mechanical | 1 | 2013 | 143 | 0.13 | Why? |
| Athletes | 2 | 2021 | 1047 | 0.12 | Why? |
| Oxygen Consumption | 1 | 2017 | 711 | 0.12 | Why? |
| Drug Combinations | 2 | 2020 | 3852 | 0.11 | Why? |
| Exercise Tolerance | 1 | 2017 | 634 | 0.11 | Why? |
| Humans | 33 | 2021 | 930598 | 0.11 | Why? |
| Equipment Contamination | 1 | 2020 | 1308 | 0.11 | Why? |
| Coronavirus | 1 | 2020 | 18339 | 0.11 | Why? |
| Diagnostic Imaging | 1 | 2019 | 1044 | 0.11 | Why? |
| Ventricular Pressure | 1 | 2010 | 25 | 0.11 | Why? |
| Long QT Syndrome | 1 | 2020 | 1047 | 0.10 | Why? |
| Myocardial Ischemia | 1 | 2017 | 781 | 0.10 | Why? |
| Chi-Square Distribution | 1 | 2013 | 961 | 0.10 | Why? |
| Pulmonary Wedge Pressure | 1 | 2010 | 53 | 0.10 | Why? |
| Muscle, Skeletal | 1 | 2017 | 915 | 0.10 | Why? |
| Sex Characteristics | 1 | 2018 | 1120 | 0.10 | Why? |
| Pandemics | 5 | 2021 | 389249 | 0.10 | Why? |
| Early Diagnosis | 1 | 2018 | 2443 | 0.10 | Why? |
| Sleep Apnea, Obstructive | 1 | 2017 | 668 | 0.10 | Why? |
| Pneumonia, Viral | 4 | 2020 | 243684 | 0.09 | Why? |
| Coronavirus Infections | 4 | 2020 | 253789 | 0.09 | Why? |
| Diagnosis, Differential | 2 | 2020 | 7220 | 0.09 | Why? |
| Prognosis | 4 | 2018 | 32490 | 0.08 | Why? |
| Ultrasonography | 2 | 2020 | 4409 | 0.08 | Why? |
| Disinfection | 1 | 2020 | 2912 | 0.08 | Why? |
| Arthritis, Rheumatoid | 1 | 2020 | 2043 | 0.08 | Why? |
| Endothelium, Vascular | 1 | 2017 | 1751 | 0.08 | Why? |
| Smartphone | 1 | 2017 | 1840 | 0.08 | Why? |
| Clinical Competence | 2 | 2018 | 3263 | 0.08 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.08 | Why? |
| Hemorrhage | 1 | 2018 | 3013 | 0.07 | Why? |
| Male | 16 | 2021 | 367725 | 0.07 | Why? |
| Antihypertensive Agents | 1 | 2017 | 1962 | 0.07 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.07 | Why? |
| Tomography, X-Ray Computed | 3 | 2020 | 25144 | 0.07 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.07 | Why? |
| Curriculum | 1 | 2018 | 3083 | 0.07 | Why? |
| Myocardial Infarction | 1 | 2020 | 3361 | 0.07 | Why? |
| Risk Assessment | 3 | 2018 | 25439 | 0.06 | Why? |
| Female | 15 | 2021 | 380317 | 0.06 | Why? |
| Cardiac Catheterization | 1 | 2010 | 882 | 0.06 | Why? |
| Multivariate Analysis | 1 | 2013 | 5440 | 0.06 | Why? |
| Betacoronavirus | 4 | 2020 | 204454 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 5277 | 0.06 | Why? |
| Middle Aged | 9 | 2018 | 270681 | 0.06 | Why? |
| Aged | 7 | 2018 | 215776 | 0.06 | Why? |
| Precipitating Factors | 1 | 2020 | 31 | 0.06 | Why? |
| Proportional Hazards Models | 1 | 2013 | 6543 | 0.05 | Why? |
| Risk Factors | 4 | 2018 | 71621 | 0.05 | Why? |
| Water-Electrolyte Imbalance | 1 | 2020 | 119 | 0.05 | Why? |
| Hypertrophy | 1 | 2017 | 86 | 0.04 | Why? |
| Italy | 2 | 2020 | 38444 | 0.04 | Why? |
| White Coat Hypertension | 1 | 2017 | 24 | 0.04 | Why? |
| 3-Iodobenzylguanidine | 1 | 2017 | 25 | 0.04 | Why? |
| Ergometry | 1 | 2017 | 6 | 0.04 | Why? |
| Synaptic Transmission | 1 | 2017 | 46 | 0.04 | Why? |
| Registries | 1 | 2018 | 12327 | 0.04 | Why? |
| Societies, Medical | 3 | 2019 | 6907 | 0.04 | Why? |
| Chemoreceptor Cells | 1 | 2017 | 15 | 0.04 | Why? |
| Baroreflex | 1 | 2017 | 54 | 0.04 | Why? |
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 9706 | 0.04 | Why? |
| Prospective Studies | 3 | 2021 | 43301 | 0.04 | Why? |
| Echocardiography, Transesophageal | 1 | 2020 | 447 | 0.04 | Why? |
| Global Health | 1 | 2020 | 13911 | 0.04 | Why? |
| Ultrasonography, Prenatal | 1 | 2020 | 471 | 0.04 | Why? |
| Return to Sport | 1 | 2021 | 456 | 0.04 | Why? |
| Cardiac Resynchronization Therapy | 1 | 2018 | 191 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2018 | 48226 | 0.04 | Why? |
| Vasodilator Agents | 1 | 2018 | 344 | 0.04 | Why? |
| Image Enhancement | 1 | 2017 | 177 | 0.04 | Why? |
| Aged, 80 and over | 2 | 2017 | 88759 | 0.04 | Why? |
| Tomography, Emission-Computed, Single-Photon | 1 | 2017 | 279 | 0.04 | Why? |
| Cardiac Imaging Techniques | 1 | 2018 | 357 | 0.04 | Why? |
| Peer Review, Research | 1 | 2019 | 407 | 0.04 | Why? |
| Drug Resistance | 1 | 2017 | 395 | 0.04 | Why? |
| Follow-Up Studies | 3 | 2018 | 17020 | 0.03 | Why? |
| Critical Care | 1 | 2018 | 14081 | 0.03 | Why? |
| Blood Pressure Monitoring, Ambulatory | 1 | 2017 | 341 | 0.03 | Why? |
| Critical Illness | 1 | 2018 | 17281 | 0.03 | Why? |
| Time Factors | 2 | 2016 | 31397 | 0.03 | Why? |
| Cholesterol | 1 | 2017 | 660 | 0.03 | Why? |
| Ribavirin | 1 | 2020 | 1182 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Drug Interactions | 1 | 2020 | 1653 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2017 | 11497 | 0.03 | Why? |
| Receptors, Interleukin-6 | 1 | 2020 | 1383 | 0.03 | Why? |
| Europe | 2 | 2019 | 12702 | 0.03 | Why? |
| Cardiovascular Agents | 1 | 2018 | 663 | 0.03 | Why? |
| Exercise Test | 1 | 2017 | 911 | 0.03 | Why? |
| Adult | 4 | 2018 | 244371 | 0.02 | Why? |
| Antiviral Agents | 1 | 2020 | 41703 | 0.02 | Why? |
| Coronary Angiography | 1 | 2016 | 2275 | 0.02 | Why? |
| Treatment Outcome | 1 | 2013 | 51732 | 0.02 | Why? |
| Arrhythmias, Cardiac | 1 | 2020 | 2510 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2018 | 22971 | 0.02 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.02 | Why? |
| Telemedicine | 1 | 2017 | 25032 | 0.02 | Why? |
| Electrocardiography | 1 | 2020 | 3957 | 0.02 | Why? |
| Lopinavir | 1 | 2020 | 4308 | 0.02 | Why? |
| Hypoxia | 1 | 2020 | 3626 | 0.02 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.02 | Why? |
| Ritonavir | 1 | 2020 | 4212 | 0.02 | Why? |
| Thromboembolism | 1 | 2018 | 2101 | 0.02 | Why? |
| Myocarditis | 1 | 2020 | 2731 | 0.02 | Why? |
| Cardiac Surgical Procedures | 1 | 2017 | 1931 | 0.02 | Why? |
| Evidence-Based Medicine | 1 | 2017 | 3228 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2017 | 7268 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Adenosine Monophosphate | 1 | 2020 | 5652 | 0.02 | Why? |
| Alanine | 1 | 2020 | 5687 | 0.02 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Retrospective Studies | 3 | 2018 | 105322 | 0.01 | Why? |
| Magnetic Resonance Imaging | 1 | 2017 | 6551 | 0.01 | Why? |
| Disease Models, Animal | 1 | 2017 | 10998 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Animals | 2 | 2019 | 78931 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.01 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.01 | Why? |
| Inflammation | 1 | 2020 | 13255 | 0.01 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Adolescent | 1 | 2016 | 86841 | 0.00 | Why? |
Cameli's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(189)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(172)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_